Meeting
2020 ASCO Virtual Scientific Program
First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes.
Authors
Yuanbin Chen
Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI
Yuanbin Chen , Luis G. Paz-Ares , Mikhail Dvorkin , Dmytro Trukhin , Niels Reinmuth , Marina Chiara Garassino , Galina Statsenko , Oleksandr Voitko , Maximilian Hochmair , Mustafa Özgüroğlu , Francesco Verderame , Libor Havel , György Losonczy , Nikolay Conev , Katsuyuki Hotta , Jun Ho Ji , Helen Broadhurst , Natalie Byrne , Piruntha Thiyagarajah , Jonathan Wade Goldman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03043872
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9068)
DOI
10.1200/JCO.2020.38.15_suppl.9068
Abstract #
9068
Poster Bd #
261
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Safety and efficacy of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): The results from a phase II single-arm trial.
First Author: Dawei Chen
Poster
2023 ASCO Annual Meeting
Updated safety and efficacy results of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) from a phase II trial.
First Author: Dawei Chen
Poster
2022 ASCO Annual Meeting
KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer.
First Author: Jacob Sands
Poster
2021 ASCO Annual Meeting
Efficacy and safety analysis of anlotinib combined with etoposide plus cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (SCLC): The final results from a phase II single-arm trial.
First Author: Tiandong Kong